These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

726 related items for PubMed ID: 7504687

  • 1. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
    Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT.
    J Clin Invest; 1993 Dec; 92(6):2569-76. PubMed ID: 7504687
    [Abstract] [Full Text] [Related]

  • 2. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells.
    Bandyopadhyay A, Zhu Y, Cibull ML, Bao L, Chen C, Sun L.
    Cancer Res; 1999 Oct 01; 59(19):5041-6. PubMed ID: 10519421
    [Abstract] [Full Text] [Related]

  • 3. Evidence for a positive role of transforming growth factor-beta in human breast cancer cell tumorigenesis.
    Arteaga CL, Dugger TC, Winnier AR, Forbes JT.
    J Cell Biochem Suppl; 1993 Oct 01; 17G():187-93. PubMed ID: 8007696
    [Abstract] [Full Text] [Related]

  • 4. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice.
    Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD, Pietenpol JA.
    Cell Growth Differ; 1993 Mar 01; 4(3):193-201. PubMed ID: 8466857
    [Abstract] [Full Text] [Related]

  • 5. Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: evidence for negative autocrine regulation by transforming growth factor beta.
    Arteaga CL, Coffey RJ, Dugger TC, McCutchen CM, Moses HL, Lyons RM.
    Cell Growth Differ; 1990 Aug 01; 1(8):367-74. PubMed ID: 2177634
    [Abstract] [Full Text] [Related]

  • 6. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
    Tobin SW, Douville K, Benbow U, Brinckerhoff CE, Memoli VA, Arrick BA.
    Oncogene; 2002 Jan 03; 21(1):108-18. PubMed ID: 11791181
    [Abstract] [Full Text] [Related]

  • 7. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
    Harthun NL, Weaver AM, Brinckerhoff LH, Deacon DH, Gonias SL, Slingluff CL.
    J Immunother; 1998 Mar 03; 21(2):85-94. PubMed ID: 9551359
    [Abstract] [Full Text] [Related]

  • 8. Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice.
    Zugmaier G, Paik S, Wilding G, Knabbe C, Bano M, Lupu R, Deschauer B, Simpson S, Dickson RB, Lippman M.
    Cancer Res; 1991 Jul 01; 51(13):3590-4. PubMed ID: 2054795
    [Abstract] [Full Text] [Related]

  • 9. Reduction of TGF-beta activity abrogates growth promoting tumor cell-cell interactions in vivo.
    Theodorescu D, Caltabiano M, Greig R, Rieman D, Kerbel RS.
    J Cell Physiol; 1991 Sep 01; 148(3):380-90. PubMed ID: 1655815
    [Abstract] [Full Text] [Related]

  • 10. Increase in immunogenicity and sensitivity to natural cell-mediated cytotoxicity following in vitro exposure of MCA105 tumor cells to ultraviolet radiation.
    Begovic M, Herberman R, Gorelik E.
    Cancer Res; 1991 Oct 01; 51(19):5153-9. PubMed ID: 1913641
    [Abstract] [Full Text] [Related]

  • 11. Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells.
    Sierra A, Price JE, García-Ramirez M, Méndez O, López L, Fabra A.
    Lab Invest; 1997 Oct 01; 77(4):357-68. PubMed ID: 9354770
    [Abstract] [Full Text] [Related]

  • 12. Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice.
    Lamszus K, Jin L, Fuchs A, Shi E, Chowdhury S, Yao Y, Polverini PJ, Laterra J, Goldberg ID, Rosen EM.
    Lab Invest; 1997 Mar 01; 76(3):339-53. PubMed ID: 9121117
    [Abstract] [Full Text] [Related]

  • 13. Treatment of transforming growth factor-beta-insensitive mouse Renca tumor by transforming growth factor-beta elimination.
    Perry K, Wong L, Liu V, Park I, Zhang Q, Rejen V, Huang X, Smith ND, Jovanovic B, Lonning S, Teicher BA, Lee C.
    Urology; 2008 Jul 01; 72(1):225-9. PubMed ID: 18295867
    [Abstract] [Full Text] [Related]

  • 14. Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family.
    Vrana JA, Stang MT, Grande JP, Getz MJ.
    Cancer Res; 1996 Nov 01; 56(21):5063-70. PubMed ID: 8895765
    [Abstract] [Full Text] [Related]

  • 15. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
    Lin CY, Chuang TF, Liao KW, Huang YJ, Pai CC, Chu RM.
    Cancer Lett; 2008 Dec 18; 272(2):285-95. PubMed ID: 18760876
    [Abstract] [Full Text] [Related]

  • 16. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta.
    Dong Z, Greene G, Pettaway C, Dinney CP, Eue I, Lu W, Bucana CD, Balbay MD, Bielenberg D, Fidler IJ.
    Cancer Res; 1999 Feb 15; 59(4):872-9. PubMed ID: 10029078
    [Abstract] [Full Text] [Related]

  • 17. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.
    Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, ten Dijke P.
    Cancer Res; 2006 Feb 15; 66(4):2202-9. PubMed ID: 16489022
    [Abstract] [Full Text] [Related]

  • 18. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
    Moore LD, Isayeva T, Siegal GP, Ponnazhagan S.
    Clin Cancer Res; 2008 Aug 01; 14(15):4961-70. PubMed ID: 18676771
    [Abstract] [Full Text] [Related]

  • 19. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro.
    Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R.
    J Bone Miner Res; 2001 Aug 01; 16(8):1486-95. PubMed ID: 11499871
    [Abstract] [Full Text] [Related]

  • 20. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
    Ghiringhelli F, Ménard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, Lecesne A, Robert C, Blay JY, Bernard J, Caillat-Zucman S, Freitas A, Tursz T, Wagner-Ballon O, Capron C, Vainchencker W, Martin F, Zitvogel L.
    J Exp Med; 2005 Oct 17; 202(8):1075-85. PubMed ID: 16230475
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.